In a mouse tumor model, lactate modulation and anti-tumor activity were evaluated through the direct target interaction of the optimized compound 18n with the cytosolic domain of SLC16A3 suggesting pharmacokinetic inhibition of SLC16A3 by 18n is a useful outcome measure for anti-tumor effects on tumor biology [34]. Here, SLC16A3 is linked to neoplasm.